DATE16 Oct

NIFTY 23,146 ▲ 0.65%BANK NIFTY 55,844 ▲ 0.06%NIFTY IT 31,924 ▲ 3.92%NIFTY PHARMA 25,782 ▼ 0.14%HBLENGINE 833 ▲ 17.27%TECHM 1,790 ▲ 8.48%RRKABEL 2,388 ▼ 8.29%CCL 1,008 ▼ 7.10%SHRIPISTON 4,630 ▲ 6.85%THANGAMAYL 5,098 ▲ 6.41%WIPRO 184 ▲ 5.95%AIIL 572 ▲ 5.64%KPITTECH 555 ▲ 5.51%APARINDS 16,033 ▼ 5.21%NIFTY 23,146 ▲ 0.65%BANK NIFTY 55,844 ▲ 0.06%NIFTY IT 31,924 ▲ 3.92%NIFTY PHARMA 25,782 ▼ 0.14%HBLENGINE 833 ▲ 17.27%TECHM 1,790 ▲ 8.48%RRKABEL 2,388 ▼ 8.29%CCL 1,008 ▼ 7.10%SHRIPISTON 4,630 ▲ 6.85%THANGAMAYL 5,098 ▲ 6.41%WIPRO 184 ▲ 5.95%AIIL 572 ▲ 5.64%KPITTECH 555 ▲ 5.51%APARINDS 16,033 ▼ 5.21%

Morning brief · Tuesday, 20 October 2026

Beta Drugs clarifies new government policy will not hit margins

Market pulse

The Nifty rose 0.65 percent to close at 23,146, propelled by a 3.92 percent surge in Nifty IT, while Bank Nifty remained flat. HBL Engineering and Tech Mahindra led the gainers, rising 17.27 percent and 8.48 percent respectively.

From the investor's mind

One post worth your time, explained

@aditya_kondawar · on X

HCL Technologies is seeing advanced artificial intelligence services scale rapidly into a critical growth driver as quarterly revenues from this segment reached 219 million dollars. Sharing insights from the company's second-quarter earnings call, Aditya Kondawar highlights that this advanced AI revenue grew by 28.4 percent quarter on quarter and 78 percent year on year. The structural shift has now pushed the annualized advanced AI revenue for the firm to 876 million dollars. This rapid scale-up underscores how deeply artificial intelligence integrations are beginning to materialize into tangible top-line contributions for major IT players.

Know more about the stock

Word in the street

What the wider market is buzzing about

Beta Drugs Limited

₹1,783Past year ▼ 1%M.cap ₹1,417 Cr

Investors are actively discussing Beta Drugs Limited, a company with a market capitalization of about 1,417 crore whose stock has fallen 1.49 percent over the past year. The central talking point is a recent conversation with the company management regarding the impact of a new government policy on manufacturer margins. Management clarified that the policy will not affect their margins, using a clear illustration. If Beta Drugs sells a drug to a retailer for 1,500 rupees and the retail price is cut from 7,000 rupees to around 3,000 or 4,000 rupees, the manufacturer margin remains completely untouched.

Know more about the stock

Yesterday's big moves